Show simple item record

dc.contributor.authorSimon-Gozalbo, Ana
dc.contributor.authorRodriguez-Blazquez, Carmen 
dc.contributor.authorForjaz, Maria João 
dc.contributor.authorMartinez-Martin, Pablo 
dc.date.accessioned2021-01-27T08:44:27Z
dc.date.available2021-01-27T08:44:27Z
dc.date.issued2020
dc.identifier.citationFront Neurol . 2020 Aug 4;11:731.es_ES
dc.identifier.issn1664-2295es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/11683
dc.description.abstractBackground: Cognitive impairment is one of the most frequent and disabling non-motor symptoms in Parkinson disease (PD) and encompasses a continuum from mild cognitive impairment (PD-MCI) to dementia (PDD). The risk factors associated with them are not completely elucidated. Objective: To characterize the presence and clinical presentation of PD-MCI and PDD in patients with idiopathic PD, examining motor and non-motor features and determining factors associated with cognitive impairment. Methods: Multicenter, cross-sectional study in 298 PD patients who underwent clinical [Hoehn and Yahr (HY) staging and Clinical Impression of Severity Index for Parkinson Disease], neurological [Scales for Outcomes in Parkinson's Disease (SCOPA)-Motor], neuropsychological (Mini Mental State Examination, SCOPA-Cognition, Frontal Assessment Battery and Clinical Dementia Rating Scale), neuropsychiatric [SCOPA-Psychiatric complications, SCOPA-Psychosocial (SCOPA-PS), and Hospital Anxiety and Depression Scale (HADS)], and health-related quality of life [Parkinson Disease Questionnaire for quality of life (PDQ-8)] assessment. Movement Disorders Society criteria were applied to classify patients as normal cognition (NC), PD-MCI, and PDD. The association between variables was explored using multivariate binary and multinomial logistic regression models. Results: Seventy-two patients (24.2%) were classified as NC, 82 (27.5%) as PD-MCI, and 144 (48.3%) as PDD. These last two groups reported more psychosocial problems related with the disease (mean SCOPA-PS, 16.27 and 10.39, respectively), compared with NC (7.28) and lower quality-of-life outcomes (PDQ-8 48.98 and 28.42, respectively) compared to NC (19.05). The logistic regression analysis showed that both cognitive impaired groups had a more severe stage of PD measured by HY [odds ratio (OR) for MCI-PD, 2.45; 95% confidence interval (CI), 1.22-4.90; OR for PDD 2.64; 95% CI, 1.17-5.98]. Specifically, age (OR, 1.30; 95% CI, 1.16-1.47), years of education (OR, 0.91; 95% CI, 0.83-0.99), disease duration (OR, 1.19; 95% CI, 1.07-1.32), HADS-D (OR, 1.20; 95% CI, 1.06-1.35), and hallucinations (OR, 2.98; 95% CI, 1.16-7.69) were related to PDD. Conclusions: Cognitive impairment in PD is associated with more severe disease stage, resulting in a global, neuropsychiatric, psychosocial, and quality-of-life deterioration. This study provides a better understanding of the great impact that cognitive impairment has within the natural history of PD and its relationship with the rest of motor and non-motor symptoms in the disease.es_ES
dc.description.sponsorshipThis study was partially funded by the QASP research project (Institute of Health Carlos III, Intramural Strategical Action in Health AESI 2018, Ref: PI18CIII/00046).es_ES
dc.language.isoenges_ES
dc.publisherFrontiers Mediaes_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectParkinson's diseasees_ES
dc.subjectclinical characteristicses_ES
dc.subjectcognitive dysfunctiones_ES
dc.subjectdementiaes_ES
dc.subjectmild cognitive impairmentes_ES
dc.subjectmotor and non-motor symptoms.es_ES
dc.titleClinical Characterization of Parkinson's Disease Patients With Cognitive Impairment.es_ES
dc.typeArtículoes_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID32849203es_ES
dc.format.volume11es_ES
dc.format.page731es_ES
dc.identifier.doi10.3389/fneur.2020.00731es_ES
dc.contributor.funderInstituto de Salud Carlos IIIes_ES
dc.description.peerreviewedes_ES
dc.relation.publisherversionhttps://doi.org/10.3389/fneur.2020.00731es_ES
dc.identifier.journalFrontiers in neurologyes_ES
dc.repisalud.centroISCIII::Centro Nacional de Epidemologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI18CIII/00046es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional